WVE News and Press, Wave Life Sciences Ltd. From 03/21/22

CAMBRIDGE, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Exe...

BOTHELL, Wash., March 21, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Michael A. Panzara, M.D....

Presentation at OPT 2022 to highlight AATD program, including reduction of liver aggregates with repeat AIMer dosing out to 19 weeks Multiple presentations and panel discussions at 3 rd Annual RNA Editing Summit to highlight Wave’s leadership in therapeutic RN...

Published data demonstrate potent, durable, and specific editing and potential for therapeutic applications in liver using a subcutaneous GalNAc-conjugated oligonucleotide approach Wave’s foundational AIMer technology avoids limitations of other base editing approaches reli...

The following slide deck was published by Wave Life Sciences Ltd. in conjunction with their 2021 Q4 earnings call. For further details see: Wave Life Sciences Ltd. 2021 Q4 - Results - Earnings Call Presentation

Wave Life Sciences Ltd. (WVE) Q4 2021 Earnings Conference Call March 3, 2022 08:30 ET Company Participants Kate Rausch - Head, Investor Relations Paul Bolno - President and Chief Executive Officer Paloma Giangrande - Vice President, Biology and Platform Development Mike Panzara - Chief Medica...

Wave Life Sciences press release (NASDAQ:WVE): Q4 GAAP EPS of -$0.61 misses by $0.06. Revenue of $1.76M (-81.4% Y/Y) misses by $11.98M. For further details see: Wave Life Sciences GAAP EPS of -$0.61 misses by $0.06, revenue of $1.76M misses by $11.98M

Clinical data from multiple novel, PN-modified stereopure oligonucleotides for ALS/FTD, DMD, and HD expected in 2022 GalNAc-AIMers restore therapeutically relevant levels of AAT for lung protection and reduce liver-damaging aggregates in preclinical study; IND enabling toxicology ...

Wave Life Sciences (NASDAQ:WVE) is scheduled to announce Q4 earnings results on Thursday, March 3rd, before market open. The consensus EPS Estimate is -$0.55 (+6.8% Y/Y) and the consensus Revenue Estimate is $13.74M (+45.6% Y/Y). For further details see: Wave Life Sciences Q4 2021 Earni...

ABUS, ARGX, ASPS, ATRS, BBY, BF.B, BIG, BILI, BJ, BURL, CAN, CNCE, CNQ, CNSL, CPG, CRH, OTCQX:DLAKF, EYPT, GLYC, GOGO, GRAB, HTOO, KR, MBT, MCS, MEI, OTCPK:MKGAF, MTLS, OXSQ, REE, REV, SBSW, OTCPK:SNCAF, SOHO, SRLP, STXS, SUP, TD, TGLS, TTC, TTSH, TWI, TZOO, UONE, UTZ, WB, WHF, WVE For Seekin...